Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial).
Rahmé R., Ades L., Thomas X., Guerci-Bresler A., Pigneux A., Vey N., Raffoux E., Castaigne S., Spertini O., Wittnebel S. et al., 2018/11. Haematologica, 103 (11) pp. e519-e521. Peer-reviewed.
ici le détail